Citations (157)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Michael A Morse, Eric Liu, Vijay N Joish, Lynn Huynh, Mu Cheng, Mei Sheng Duh, Kiernan Seth, Pablo Lapuerta & David C Metz. (2020) Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study. Cancer Management and Research 12, pages 6607-6614.
Read now
Read now
Cristina Saavedra, Jorge Barriuso, Mairéad G McNamara, Juan W Valle & Angela Lamarca. (2019) Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. Cancer Management and Research 11, pages 7537-7556.
Read now
Read now
Diamantis I. Tsilimigras, Malcolm H. Squires, Jordan M. Cloyd & Timothy M. Pawlik. (2019) Treatment strategies for neuroendocrine liver metastases: an update. Expert Opinion on Orphan Drugs 7:7-8, pages 327-335.
Read now
Read now
Sara Pusceddu, Daniela Femia, Giuseppe Lo Russo, Silvia Ortolani, Massimo Milione, Marco Maccauro, Claudio Vernieri, Natalie Prinzi, Laura Concas, Livia Leuzzi, Filippo De Braud & Roberto Buzzoni. (2016) Update on medical treatment of small intestinal neuroendocrine tumors. Expert Review of Anticancer Therapy 16:9, pages 969-976.
Read now
Read now
Sara Massironi, Dario Conte & Roberta Elisa Rossi. (2016) Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Scandinavian Journal of Gastroenterology 51:5, pages 513-523.
Read now
Read now
Kjell Öberg. (2015) Neuroendocrine gastro-enteropancreatic tumors – from eminence based to evidence-based medicine – A Scandinavian view. Scandinavian Journal of Gastroenterology 50:6, pages 727-739.
Read now
Read now
Nina Nandy & Constantin A Dasanu. (2013) Management of advanced and/or metastatic carcinoid tumors: historical perspectives and emerging therapies. Expert Opinion on Pharmacotherapy 14:12, pages 1649-1658.
Read now
Read now
Tine Gregersen, Henning Grønbæk, Jonas Worsøe, Vincent Schlageter, Søren Laurberg & Klaus Krogh. (2011) Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors. Scandinavian Journal of Gastroenterology 46:7-8, pages 895-902.
Read now
Read now
Lowell Anthony & Pamela U. Freda. (2009) From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Current Medical Research and Opinion 25:12, pages 2989-2999.
Read now
Read now
IM Modlin, M Kidd, I Drozdov, Z-L Siddique & BI Gustafsson. (2008) Pharmacotherapy of neuroendocrine cancers. Expert Opinion on Pharmacotherapy 9:15, pages 2617-2626.
Read now
Read now
Jennifer A Chan$suffix/text()$suffix/text() & Matthew H Kulke$suffix/text()$suffix/text(). (2007) Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opinion on Emerging Drugs 12:2, pages 253-270.
Read now
Read now
Martijn Van Essen, Eric P. Krenning, Marion De Jong, Roelf Valkema & Dik J. Kwekkeboom. (2007) Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncologica 46:6, pages 723-734.
Read now
Read now
G. J. Krejs. (1996) Gastrointestinal Endocrine Tumors. Scandinavian Journal of Gastroenterology 31:sup220, pages 121-123.
Read now
Read now
Articles from other publishers (144)
Stijn Hentzen, Kathan Mehta, Raed Moh’d Taiseer Al-Rajabi, Anwaar Saeed, Joaquina Celebre Baranda, Stephen K. Williamson, Weijing Sun & Anup Kasi. (2023) Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy. Exploration of Targeted Anti-tumor Therapy, pages 396-405.
Crossref
Crossref
Alok Swaroop, Diana Saleiro & Leonidas C. Platanias. (2023) Interferon and myeloproliferative neoplasms: Evolving therapeutic approaches. BioEssays 45:3.
Crossref
Crossref
Anna Koumarianou, Kosmas Daskalakis, Marina Tsoli, Gregory Kaltsas & Marianne Pavel. (2022) Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome. Journal of Neuroendocrinology 34:7.
Crossref
Crossref
Rosaria M. Ruggeri, Barbara Altieri, Erika Grossrubatcher, Roberto Minotta, Maria Grazia Tarsitano, Virginia Zamponi, Andrea MIsidori, Antongiulio Faggiano & Anna Maria Colao. (2022) Sex differences in carcinoid syndrome: A gap to be closed. Reviews in Endocrine and Metabolic Disorders 23:3, pages 659-669.
Crossref
Crossref
Neil Grey, Michael Silosky, Christopher H Lieu & Bennett B Chin. (2022) Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors. World Journal of Gastroenterology 28:17, pages 1768-1780.
Crossref
Crossref
Mohammed B. Allaw, Jeffrey M. Switchenko, Lana Khalil, Christina Wu, Olatunji B. Alese, Mehmet Akce, Amber Draper, Aaron T. Jones, Bassel El-Rayes & Walid Shaib. (2022) Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. Oncology 100:3, pages 131-139.
Crossref
Crossref
Natalie Prinzi, Roberta Elisa Rossi, Claudia Proto, Giovanni Leuzzi, Alessandra Raimondi, Martina Torchio, Massimo Milione, Francesca Corti, Elena Colombo, Michele Prisciandaro, Tommaso Cascella, Carlo Spreafico, Teresa Beninato, Jorgelina Coppa, Giuseppe Lo Russo, Maria Di Bartolomeo, Filippo de Braud & Sara Pusceddu. (2021) Recent Advances in the Management of Typical and Atypical Lung Carcinoids. Clinical Lung Cancer 22:3, pages 161-169.
Crossref
Crossref
Joseph S. Dillon, Matthew H. Kulke, Dieter Hörsch, Lowell B. Anthony, Richard R. P. Warner, Emily Bergsland, Staffan Welin, Thomas M. O’Dorisio, Pamela L. Kunz, Chad McKee, Pablo Lapuerta, Phillip Banks & Marianne Pavel. (2020) Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. Journal of Gastrointestinal Cancer 52:1, pages 212-221.
Crossref
Crossref
Sylvia L. Asa, Stefano La Rosa, Olca Basturk, Volkan Adsay, Marianna Minnetti & Ashley B. Grossman. (2021) Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors. Endocrine Pathology 32:1, pages 169-191.
Crossref
Crossref
Chengyue Jin, Ajay Nair Sharma, Balasingam Thevakumar, Muhammad Majid, Shahad Al Chalaby, Nene Takahashi, Ashraf Tanious, Aro Daniela Arockiam, Neil Beri & Ezra A. Amsterdam. (2021) Carcinoid Heart Disease: Pathophysiology, Pathology, Clinical Manifestations, and Management. Cardiology 146:1, pages 65-73.
Crossref
Crossref
Natalie Prinzi, Roberta Elisa Rossi, Giovanni Leuzzi & Sara Pusceddu. 2021. Neuroendocrine Neoplasia Management. Neuroendocrine Neoplasia Management
163
178
.
Aura D. Herrera-Martínez, Richard A. Feelders, Rosanna Van den Dungen, Fadime Dogan-Oruc, Peter M. van Koetsveld, Justo P. Castaño, Wouter W. de Herder & Leo J. Hofland. (2020) Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells. Neuroendocrinology 110:5, pages 351-363.
Crossref
Crossref
D. Magalhães, I. L. Sampaio, G. Ferreira, P. Bogalho, D. Martins-Branco, R. Santos & H. Duarte. (2018) Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review. Journal of Endocrinological Investigation 42:3, pages 249-260.
Crossref
Crossref
Pradhum Ram, Jorge L. Penalver, Kevin Bryan U. Lo, Janani Rangaswami & Gregg S. Pressman. (2019) Carcinoid Heart Disease: Review of Current Knowledge. Texas Heart Institute Journal 46:1, pages 21-27.
Crossref
Crossref
Edward M. Wolin & Al Bowen Benson III. (2019) Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review. Oncology 96:6, pages 273-289.
Crossref
Crossref
Mauro Cives, Eleonora Pellè, Franco Silvestris & Jonathan Strosberg. 2019. Oncogenomics. Oncogenomics
575
589
.
Aura D. Herrera-Martínez, Johannes Hofland, Leo J. Hofland, Tessa Brabander, Ferry A. L. M. Eskens, María A. Gálvez Moreno, Raúl M. Luque, Justo P. Castaño, Wouter W. de Herder & Richard A. Feelders. (2018) Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 79:1, pages 21-42.
Crossref
Crossref
Stephanie M Barrows, Beilei Cai, Catherine Copley-Merriman, Kelly R Wright, Colleen V Castro & Raoudha Soufi-Mahjoubi. (2018) Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. World Journal of Meta-Analysis 6:2, pages 9-20.
Crossref
Crossref
Keunyoung Kim & Seong-Jang Kim. (2017) Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors. Nuclear Medicine and Molecular Imaging 52:3, pages 208-215.
Crossref
Crossref
Joseph S Dillon & Chandrikha Chandrasekharan. (2018) Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. Future Oncology 14:12, pages 1155-1164.
Crossref
Crossref
Jonathan Strosberg. 2018. The American Cancer Society's Oncology in Practice. The American Cancer Society's Oncology in Practice
552
570
.
Gregory Kaltsas, Krystallenia I. Alexandraki & Ashley B. Grossman. 2018. Endocrine and Metabolic Medical Emergencies. Endocrine and Metabolic Medical Emergencies
472
483
.
James N. Gerson, Ronald M. Witteles, Daniel T. Chang, Ramin E. Beygui, Andrei H. Iagaru & Pamela L. Kunz. (2017) Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor. Pancreas 46:10, pages 1381-1385.
Crossref
Crossref
Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Ana Custodio, Enrique Grande, Jaume Capdevila, Carlos López, Alex Teule & Rocío Garcia-Carbonero. (2017) Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Current Oncology Reports 19:11.
Crossref
Crossref
Ioana Lambrescu, Simona Fica, Diana Martins, Francesca Spada, Chiara Cella, Emilio Bertani, Manila Rubino, Bianca Gibelli, Chiara Grana, Guido Bonomo, Luigi Funicelli, Davide Ravizza, Eleonora Pisa, Dario Zerini, Antonio Ungaro & Nicola Fazio. (2017) Metronomic and metronomic-like therapies in neuroendocrine tumors – Rationale and clinical perspectives. Cancer Treatment Reviews 55, pages 46-56.
Crossref
Crossref
Mauro Cives & Jonathan Strosberg. (2017) Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. Current Treatment Options in Oncology 18:3.
Crossref
Crossref
Jonathan Strosberg, Ghassan El-Haddad, Edward Wolin, Andrew Hendifar, James Yao, Beth Chasen, Erik Mittra, Pamela L. Kunz, Matthew H. Kulke, Heather Jacene, David Bushnell, Thomas M. O’Dorisio, Richard P. Baum, Harshad R. Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy Hobday, Ebrahim Delpassand, Eric Van Cutsem, Al Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Mora, Jordan Berlin, Enrique Grande, Nicholas Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L. Erion, Philippe Ruszniewski, Dik Kwekkeboom & Eric Krenning. (2017)
Phase 3 Trial of
177
Lu-Dotatate for Midgut Neuroendocrine Tumors
. New England Journal of Medicine 376:2, pages 125-135.
Crossref
Crossref
Krystallenia I. Alexandraki, Aggeliki Karapanagioti, Ioannis Karoumpalis, Georgios Boutzios & Gregory A. Kaltsas. (2017) Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. BioMed Research International 2017, pages 1-12.
Crossref
Crossref
Georgios K Dimitriadis, Martin O Weickert, Harpal S Randeva, Gregory Kaltsas & Ashley Grossman. (2016) Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 23:9, pages R423-R436.
Crossref
Crossref
Dik J. Kwekkeboom & Eric P. Krenning. 2016. Radionuclide Peptide Cancer Therapy. Radionuclide Peptide Cancer Therapy
233
237
.
Dik J. Kwekkeboom & Eric P. Krenning. (2016) Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. Hematology/Oncology Clinics of North America 30:1, pages 179-191.
Crossref
Crossref
Claire K. Mulvey & Emily K. Bergsland. (2016) Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors. Hematology/Oncology Clinics of North America 30:1, pages 63-82.
Crossref
Crossref
Kjell Öberg. 2016. Endocrinology: Adult and Pediatric. Endocrinology: Adult and Pediatric
2615
2627.e3
.
Daniel C. McFarland, Indu Varier & Krzysztof Misiukiewicz. 2016. Controversies in Thyroid Surgery. Controversies in Thyroid Surgery
203
228
.
Aejaz Nasir, Ujalla Sheikh, Jalil Muhammad & Domenico Coppola. 2016. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances
445
455
.
Daniel C. McFarland, Rajan P. Dang, Brett A. Miles & Krzysztof Misiukiewicz. (2015) Four Difficult Thyroid Cancer Cases: Incorporating Medical Therapies. Seminars in Oncology 42:6, pages e83-e98.
Crossref
Crossref
Peter J. Carolan & Daniel C. Chung. 2015. Yamada' s Textbook of Gastroenterology. Yamada' s Textbook of Gastroenterology
1782
1807
.
Edward M. Wolin. (2015) Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations. The Oncologist 20:10, pages 1123-1131.
Crossref
Crossref
Tine Gregersen, Anne-Mette Haase, Vincent Schlageter, Henning Gronbaek & Klaus Krogh. (2015) Regional Gastrointestinal Transit Times in Patients With Carcinoid Diarrhea: Assessment With the Novel 3D-Transit System. Journal of Neurogastroenterology and Motility 21:3, pages 423-432.
Crossref
Crossref
Esther I. van Vliet, Boen L.R. Kam, Jaap J.M. Teunissen, Marion de Jong, Eric P. Krenning & Dik J. Kwekkeboom. 2015. Somatostatin Analogues. Somatostatin Analogues
214
229
.
Jonathan Strosberg. 2015. Neuroendocrine Tumours. Neuroendocrine Tumours
523
534
.
Jessica E. Maxwell, Scott K. Sherman, Thomas M. O'Dorisio & James R. Howe. (2014) Medical management of metastatic medullary thyroid cancer. Cancer 120:21, pages 3287-3301.
Crossref
Crossref
Jonathan R. Strosberg. (2014) Systemic Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS): Cuirrent Approaches and Future Options. Endocrine Practice 20:2, pages 167-175.
Crossref
Crossref
Davide Campana, Gabriele Capurso, Stefano Partelli, Francesca Nori, Francesco Panzuto, Domenico Tamburrino, Giulia Cacciari, Gianfranco Delle Fave, Massimo Falconi & Paola Tomassetti. (2013) Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. European Journal of Nuclear Medicine and Molecular Imaging 40:8, pages 1197-1205.
Crossref
Crossref
Jonathan R. Strosberg, George A. Fisher, Al B. Benson, Jennifer L. Malin, Dasha Cherepanov & Michael S. Broder. (2013) Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors. Pancreas 42:3, pages 397-404.
Crossref
Crossref
Christos Toumpanakis & Martyn E. Caplin. (2013) Update on the Role of Somatostatin Analogs for the Treatment of Patients With Gastroenteropancreatic Neuroendocrine Tumors. Seminars in Oncology 40:1, pages 56-68.
Crossref
Crossref
Marianne Pavel, Mark Kidd & Irvin Modlin. (2013) Systemic Therapeutic Options for Carcinoid. Seminars in Oncology 40:1, pages 84-99.
Crossref
Crossref
Hendrik Bergsma, Esther I. van Vliet, Jaap J.M. Teunissen, Boen L.R. Kam, Wouter W. de Herder, Robin P. Peeters, Eric P. Krenning & Dik J. Kwekkeboom. (2012) Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Practice & Research Clinical Gastroenterology 26:6, pages 867-881.
Crossref
Crossref
Jonathan Strosberg. (2012) Neuroendocrine tumours of the small intestine. Best Practice & Research Clinical Gastroenterology 26:6, pages 755-773.
Crossref
Crossref
F.P. Costa, B. Gumz & B. Pasche. (2012) Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours. Best Practice & Research Clinical Gastroenterology 26:6, pages 843-854.
Crossref
Crossref
Koji Tsuta, Ignacio I. Wistuba & Cesar A. Moran. (2012) Differential expression of somatostatin receptors 1–5 in neuroendocrine carcinoma of the lung. Pathology - Research and Practice 208:8, pages 470-474.
Crossref
Crossref
Gou Mizutani, Yoko Nakanishi, Noriko Watanabe, Taku Honma, Yukari Obana, Toshimi Seki, Sumie Ohni & Norimichi Nemoto. (2012) Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry. ACTA HISTOCHEMICA ET CYTOCHEMICA 45:3, pages 167-176.
Crossref
Crossref
Sowon Oh, Vikas Prasad, Dong Soo Lee & R. P. Baum. (2011) Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. International Journal of Molecular Imaging 2011, pages 1-7.
Crossref
Crossref
Saima Khan, Eric P. Krenning, Martijn van Essen, Boen L. Kam, Jaap J. Teunissen & Dik J. Kwekkeboom. (2011)
Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [
177
Lu-DOTA
0
,Tyr
3
]Octreotate
. Journal of Nuclear Medicine 52:9, pages 1361-1368.
Crossref
Crossref
Lucy B. Wallace & Eren Berber. (2011) Percutaneous and Video-Assisted Ablation of Endocrine Tumors. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 21:4, pages 255-259.
Crossref
Crossref
M. S. Khan, F. El-Khouly, P. Davies, C. Toumpanakis & M. E. Caplin. (2011) Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Alimentary Pharmacology & Therapeutics 34:2, pages 235-242.
Crossref
Crossref
Ginger J. Gardner, Diane Reidy-Lagunes & Paola A. Gehrig. (2011) Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. Gynecologic Oncology 122:1, pages 190-198.
Crossref
Crossref
M. Pavel. (2011) Medizinische Therapie und Chemotherapie von neuroendokrinen TumorenMedical therapy of neuroendocrine tumors. Der Onkologe 17:7, pages 592-601.
Crossref
Crossref
M. Pavel. (2011) Metastasierte neuroendokrine NeoplasienMetastatic neuroendocrine neoplasms. Der Chirurg 82:7, pages 612-617.
Crossref
Crossref
Jennifer A. Chan & Matthew H. Kulke. (2011) New Treatment Options for Patients with Advanced Neuroendocrine Tumors. Current Treatment Options in Oncology 12:2, pages 136-148.
Crossref
Crossref
Jonathan R. StrosbergAsima CheemaLarry K. Kvols. (2011) A Review of Systemic and Liver-Directed Therapies for Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic Tract. Cancer Control 18:2, pages 127-137.
Crossref
Crossref
Sanjeev Bhattacharyya, Christos Toumpanakis, Deepika Chilkunda, Martyn Evan Caplin & Joseph Davar. (2011) Risk Factors for the Development and Progression of Carcinoid Heart Disease. The American Journal of Cardiology 107:8, pages 1221-1226.
Crossref
Crossref
Chandrajit P. Raut & Matthew H. Kulke. (2011) Targeted Therapy in Advanced Well-Differentiated Neuroendocrine Tumors. The Oncologist 16:3, pages 286-295.
Crossref
Crossref
Soe T. Maunglay, Julia A. Cogburn & Pamela N. Munster. 2011. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures
165
190
.
Hizir Yakup Akyildiz, Jamie Mitchell, Mira Milas, Allan Siperstein & Eren Berber. (2010) Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: Long-term follow-up. Surgery 148:6, pages 1288-1293.
Crossref
Crossref
Kjell E. Öberg, Jean–Claude Reubi, Dik J. Kwekkeboom & Eric P. Krenning. (2010) Role of Somatostatins in Gastroenteropancreatic Neuroendocrine Tumor Development and Therapy. Gastroenterology 139:3, pages 742-753.e1.
Crossref
Crossref
Alexandria T. Phan, Kjell Öberg, Junsung Choi, Lynn H. Harrison, Manal M. Hassan, Jonathan R. Strosberg, Eric P. Krenning, Walter Kocha, Eugene A. Woltering & William J. Maples. (2010) NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. Pancreas 39:6, pages 784-798.
Crossref
Crossref
Martijn van Essen, Dik J. Kwekkeboom, Wouter W. de Herder, Lisa Bodei, Boen L. R. Kam, Marion de Jong, Roelf Valkema & Eric P. Krenning. 2010. Monoclonal Antibody and Peptide‐Targeted Radiotherapy of Cancer. Monoclonal Antibody and Peptide‐Targeted Radiotherapy of Cancer
121
138
.
Enrique Grande, Juan José Díez, Vanessa Pachón & Alfredo Carrato. (2010) Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). Clinical and Translational Oncology 12:7, pages 481-492.
Crossref
Crossref
J.B. Cwikla, A. Sankowski, N. Seklecka, J.R. Buscombe, A. Nasierowska-Guttmejer, K.G. Jeziorski, R. Mikolajczak, D. Pawlak, K. Stepien & J. Walecki. (2010) Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Annals of Oncology 21:4, pages 787-794.
Crossref
Crossref
Martijn van Essen, Eric P. Krenning, Boen L.R. Kam, Wouter W. de Herder, Richard A. Feelders & Dik J. Kwekkeboom. (2010)
Salvage Therapy with
177
Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
. Journal of Nuclear Medicine 51:3, pages 383-390.
Crossref
Crossref
Dik J. Kwekkeboom, Wouter W. de Herder, Casper H.J. van Eijck, Boen L. Kam, Martijn van Essen, Jaap J.M. Teunissen & Eric P. Krenning. (2010) Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. Seminars in Nuclear Medicine 40:2, pages 78-88.
Crossref
Crossref
I. M. MODLIN, M. PAVEL, M. KIDD & B. I. GUSTAFSSON. (2009) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Alimentary Pharmacology & Therapeutics 31:2, pages 169-188.
Crossref
Crossref
Barbro Eriksson & Kjell Öberg. 2010. Endocrinology. Endocrinology
2774
2786
.
C. TOUMPANAKIS, J. GARLAND, L. MARELLI, R. SRIRAJASKANTHAN, J. SOH, P. DAVIES, J. BUSCOMBE & M. E. CAPLIN. (2009) Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Alimentary Pharmacology & Therapeutics 30:7, pages 733-740.
Crossref
Crossref
Vishal Ghevariya, Anju Malieckal, Nehal Ghevariya, Mohammed Mazumder & Sury Anand. (2009) Carcinoid Tumors of the Gastrointestinal Tract. Southern Medical Journal 102:10, pages 1032-1040.
Crossref
Crossref
Mustafa Khasraw, Anthony Gill, Tim Harrington, Nick Pavlakis & Irvin Modlin. (2009) Management of Advanced Neuroendocrine Tumors With Hepatic Metastasis. Journal of Clinical Gastroenterology 43:9, pages 838-847.
Crossref
Crossref
Martijn van Essen, Eric P. Krenning, Boen L. R. Kam, Marion de Jong, Roelf Valkema & Dik J. Kwekkeboom. (2009) Peptide-receptor radionuclide therapy for endocrine tumors. Nature Reviews Endocrinology 5:7, pages 382-393.
Crossref
Crossref
Jennifer A. Chan & Matthew H. Kulke. (2009) Progress in the treatment of neuroendocrine tumors. Current Oncology Reports 11:3, pages 193-199.
Crossref
Crossref
G. J. Krejs. 2009. Intestinal Disorders. Intestinal Disorders
144
149
.
Alexandria T. Phan, James C. Yao & Douglas B. Evans. (2008) Treatment options for metastatic neuroendocrine tumors. Surgery 144:6, pages 895-898.
Crossref
Crossref
Mazhar U. Khan & R. Edward Coleman. (2008) Diagnosis and therapy of carcinoid tumors—current state of the art and future directions. Nuclear Medicine and Biology 35, pages S77-S91.
Crossref
Crossref
Dik J. Kwekkeboom, Wouter W. de Herder, Boen L. Kam, Casper H. van Eijck, Martijn van Essen, Peter P. Kooij, Richard A. Feelders, Maarten O. van Aken & Eric P. Krenning. (2008)
Treatment With the Radiolabeled Somatostatin Analog [
177
Lu-DOTA
0
,Tyr
3
]Octreotate: Toxicity, Efficacy, and Survival
. Journal of Clinical Oncology 26:13, pages 2124-2130.
Crossref
Crossref
James C. Yao, Alexandria Phan, Paulo M. Hoff, Helen X. Chen, Chusilp Charnsangavej, Sai-Ching J. Yeung, Kenneth Hess, Chaan Ng, James L. Abbruzzese & Jaffer A. Ajani. (2008) Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b. Journal of Clinical Oncology 26:8, pages 1316-1323.
Crossref
Crossref
O. Corcos, D. O’Toole & P. Ruszniewski. 2008. Tumeurs endocrines thoraciques et digestives. Tumeurs endocrines thoraciques et digestives
195
213
.
M. C. Champaneria, I. M. Modlin, I. Latich, J. Bornschein, I. Drozdov & M. Kidd. 2008. Molecular Targeting in Oncology. Molecular Targeting in Oncology
585
637
.
Peter J. Mazzaglia, Eren Berber & Allan E. Siperstein. (2007) Radiofrequency Thermal Ablation of Metastatic Neuroendocrine Tumors in the Liver. Current Treatment Options in Oncology 8:4, pages 322-330.
Crossref
Crossref
Peter J. Mazzaglia, Eren Berber, Mira Milas & Allan E. Siperstein. (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142:1, pages 10-19.
Crossref
Crossref
Eric K. Nakakura, Alan P. Venook & Emily K. Bergsland. (2007) Systemic and Regional Nonsurgical Therapy—What Is the Optimal Strategy for Metastatic Neuroendocrine Cancer?. Surgical Oncology Clinics of North America 16:3, pages 639-651.
Crossref
Crossref
Didier D. Malis, Nagi M. Demian, Luciano Lemos & Mark E. Wong. (2007) Carcinoid Tumor Presenting as Trismus: Immunohistochemical Evidence of Metastatic Lung Disease to the Infratemporal Fossa. Journal of Oral and Maxillofacial Surgery 65:7, pages 1382-1388.
Crossref
Crossref
Dik J. Kwekkeboom, Jaap J.M. Teunissen, Boen L. Kam, Roelf Valkema, Wouter W. de Herder & Eric P. Krenning. (2007) Treatment of Patients Who Have Endocrine Gastroenteropancreatic Tumors with Radiolabeled Somatostatin Analogues. Hematology/Oncology Clinics of North America 21:3, pages 561-573.
Crossref
Crossref
Matthew H. Kulke. (2007) Clinical Presentation and Management of Carcinoid Tumors. Hematology/Oncology Clinics of North America 21:3, pages 433-455.
Crossref
Crossref
Matthew H. Kulke. (2007) New developments in the treatment of gastrointestinal neuroendocrine tumors. Current Oncology Reports 9:3, pages 177-183.
Crossref
Crossref
Ramon Salazar. (2007) Respuesta de los autores. Medicina Clínica 128:9, pages 357-358.
Crossref
Crossref
Jonathan Buscaglia, Jon Davison & Sanjay Jagannath. (2007) A Pain in the Belly. The American Journal of Medicine 120:2, pages 133-135.
Crossref
Crossref
R. Arnold, B. Eriksson & K. Öberg. 2007. Therapiekonzepte Onkologie. Therapiekonzepte Onkologie
874
882
.
David C. Madoff, Sanjay Gupta, Kamran Ahrar, Ravi Murthy & James C. Yao. (2006) Update on the Management of Neuroendocrine Hepatic Metastases. Journal of Vascular and Interventional Radiology 17:8, pages 1235-1250.
Crossref
Crossref
Chandrajit P. Raut, Matthew H. Kulke, Jonathan N. Glickman, Richard S. Swanson & Stanley W. Ashley. (2006) Carcinoid Tumors. Current Problems in Surgery 43:6, pages 391-450.
Crossref
Crossref
Irvin M. Modlin, Igor Latich, Mark Kidd, Michelle Zikusoka & Geeta Eick. (2006) Therapeutic Options for Gastrointestinal Carcinoids. Clinical Gastroenterology and Hepatology 4:5, pages 526-547.
Crossref
Crossref
Yoshimi Nakajima. (2006) Living-related liver transplantation for multiple liver metastases from rectal carcinoid tumor: A case report. World Journal of Gastroenterology 12:11, pages 1805.
Crossref
Crossref
Aejaz Nasir, Mats Stridsberg, Jonathan Strosberg, Phi-Huynh Su, Sandra Livingston, Humaira A. Malik, Scott T. Kelley, Barbara A. Centeno, Domenico Coppola, Mokenge E. Malafa, Timothy J. Yeatman & Larry K. Kvols. (2017) Somatostatin Receptor Profiling in Hepatic Metastases from Small Intestinal and Pancreatic Neuroendocrine Neoplasms: Immunohistochemical Approach with Potential Clinical Utility. Cancer Control 13:1, pages 52-60.
Crossref
Crossref
Jean-Marc Thomassin, Arnaud Deveze & Marie-Anne Chrestian. (2006) Systè;me neuroendocrinien disséminé et pathologie cervicofaciale. EMC - Oto-rhino-laryngologie 1:1, pages 1-14.
Crossref
Crossref
Willscott E. Naugler & Gordon C. Hunt. 2006. Endoscopic Oncology. Endoscopic Oncology
161
172
.
G T Deans & R A J Spence. (1995) Neoplastic lesions of the appendix. British Journal of Surgery 82:3, pages 299-306.
Crossref
Crossref
Julia J. Scialla & Anna R. Hemnes. (2005) A pressing situation. The American Journal of Medicine 118:12, pages 1347-1349.
Crossref
Crossref
Matthew Kulke. (2005) Advances in the treatment of neuroendocrine tumors. Current Treatment Options in Oncology 6:5, pages 397-409.
Crossref
Crossref
Paola Sartori, Chiara Mussi, Carlo Angelini, Stefano Crippa, Roberto Caprotti & Franco Uggeri. (2005) Palliative management strategies of advanced gastrointestinal carcinoid neoplasms. Langenbeck's Archives of Surgery 390:5, pages 391-396.
Crossref
Crossref
Weijing Sun, Stuart Lipsitz, Paul Catalano, James A. Mailliard & Daniel G. Haller. (2005) Phase II/III Study of Doxorubicin With Fluorouracil Compared With Streptozocin With Fluorouracil or Dacarbazine in the Treatment of Advanced Carcinoid Tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology 23:22, pages 4897-4904.
Crossref
Crossref
U. Plöckinger & B. Wiedenmann. (2005) Management of metastatic endocrine tumours. Best Practice & Research Clinical Gastroenterology 19:4, pages 553-576.
Crossref
Crossref
Irvin M. Modlin, Mark Kidd, Igor Latich, Michelle N. Zikusoka & Michael D. Shapiro. (2005) Current Status of Gastrointestinal Carcinoids. Gastroenterology 128:6, pages 1717-1751.
Crossref
Crossref
Dik J. Kwekkeboom, Jaap J. Teunissen, Willem H. Bakker, Peter P. Kooij, Wouter W. de Herder, Richard A. Feelders, Casper H. van Eijck, Jan-Paul Esser, Boen L. Kam & Eric P. Krenning. (2005)
Radiolabeled Somatostatin Analog [
177
Lu-DOTA
0
,Tyr
3
]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
. Journal of Clinical Oncology 23:12, pages 2754-2762.
Crossref
Crossref
Johanna M. Zuetenhorst & Babs G. Taal. (2005) Metastatic Carcinoid Tumors: A Clinical Review. The Oncologist 10:2, pages 123-131.
Crossref
Crossref
Irvin M. Modlin, Michael D. Shapiro & Mark Kidd. (2004) An Analysis of Rare Carcinoid Tumors: Clarifying These Clinical Conundrums. World Journal of Surgery 29:1, pages 92-101.
Crossref
Crossref
Stergios Moschos, Sai Varanasi & John M. Kirkwood. 2005. Cytokines and Cancer. Cytokines and Cancer
207
241
.
Gregory A. Kaltsas, G. Michael Besser & Ashley B. Grossman. (2004) The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors. Endocrine Reviews 25:3, pages 458-511.
Crossref
Crossref
Dimitris Dimitroulopoulos. (2004) Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis. World Journal of Gastroenterology 10:24, pages 3628.
Crossref
Crossref
Keith Stuart, Donna E. Levy, Tom Anderson, Constantine A. Axiotis, Janice P. Dutcher, Andrew Eisenberg, John K. Erban & Al Bowen Benson III. (2004) Phase II Study of Interferon Gamma in Malignant Carcinoid Tumors (E9292): A Trial of the Eastern Cooperative Oncology Group. Investigational New Drugs 22:1, pages 75-81.
Crossref
Crossref
Eren Berber & Allan E. Siperstein. (2003) Laparoscopic Radiofrequency Ablation of Neuroendocrine Liver Metastases. Problems in General Surgery 20:3, pages 134-142.
Crossref
Crossref
D. J. Kwekkeboom, W. H. Bakker, B. L. Kam, J. J. M. Teunissen, P. P. M. Kooij, W. W. Herder, R. A. Feelders, C. H. J. Eijck, M. Jong, A. Srinivasan, J. L. Erion & E. P. Krenning. (2003) Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. European Journal of Nuclear Medicine and Molecular Imaging 30:3, pages 417-422.
Crossref
Crossref
J. Garland, J. R. Buscombe, C. Bouvier, P. Bouloux, M. H. Chapman, A. C. Chow, N. Reynolds & M. E. Caplin. (2003) Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Alimentary Pharmacology & Therapeutics 17:3, pages 437-444.
Crossref
Crossref
Wey L. Leong & Janice L. Pasieka. (2002) Regression of metastatic carcinoid tumors with octreotide therapy: Two case reports and a review of the literature. Journal of Surgical Oncology 79:3, pages 180-187.
Crossref
Crossref
Sundar Santhanam, Marios Decatris & Ken O??Byrne. (2002) Potential of Interferon-?? in Solid Tumours. BioDrugs 16:5, pages 349-372.
Crossref
Crossref
J.M. Thomassin, A. Deveze & M.A. Chrestian. (2002) Sistema neuroendocrino difuso y patología cervicofacial. EMC - Otorrinolaringología 31:4, pages 1-15.
Crossref
Crossref
Maurizio Ponz de LeonMaurizio Ponz de Leon. 2002. Colorectal Cancer. Colorectal Cancer
275
284
.
Marie-Louise H. Fj�llskog, Dan. P. K. Granberg, Staffan L. V. Welin, Christopher Eriksson, Kjell E. �berg, Eva T. Janson & Barbro K. Eriksson. (2001) Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:5, pages 1101-1107.
Crossref
Crossref
Kanakadurga Rao Poduri & Edward M. Schnitzer. (2001) Carcinoid tumor mistaken for persistent neurogenic bowel symptoms in a patient with paraplegia: A case report. Archives of Physical Medicine and Rehabilitation 82:7, pages 996-999.
Crossref
Crossref
Renier Brentjens & Leonard Saltz. (2001) ISLET CELL TUMORS OF THE PANCREAS. Surgical Clinics of North America 81:3, pages 527-542.
Crossref
Crossref
Tomassetti, Migliori, Corinaldesi & Gullo. (2001) Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Alimentary Pharmacology & Therapeutics 14:5, pages 557-560.
Crossref
Crossref
Dermot O'Toole, Michel Ducreux, Gilles Bommelaer, Jean-Louis Wemeau, Olivier Bouch�, France Catus, Jo�lle Blumberg & Philippe Ruszniewski. (2000) Treatment of carcinoid syndrome. Cancer 88:4, pages 770-776.
Crossref
Crossref
Matthias Schott, Werner A. Scherbaum & Joachim Feldkamp. (2000) Medikamentöse Therapie endokriner KarzinomeMedical therapy of endocrine carcinomas. Part I: Thyroid carcinomas, adrenal carcinomas and parathyroid carcinomas. Medizinische Klinik 95:1, pages 20-25.
Crossref
Crossref
Christian A. Koch, Norio Azumi, Mary A. Furlong, Reena C. Jha, Theresa E. Kehoe, Catherine H. Trowbridge, Thomas M. O’Dorisio, George P. Chrousos & Stephen C. Clement. (1999) Carcinoid Syndrome Caused by an Atypical Carcinoid of the Uterine Cervix. The Journal of Clinical Endocrinology & Metabolism 84:11, pages 4209-4213.
Crossref
Crossref
Margareta Frank, Klaus J Klose, Matthias Wied, Natascha Ishaque, Carmen Schade-Brittinger & Rudolf Arnold. (1999) Combination Therapy With Octreotide and α-Interferon:. American Journal of Gastroenterology 94:5, pages 1381-1387.
Crossref
Crossref
I Madeira & P Ruszniewski. (1999) Tumeurs carcinoïdes digestives : mise au point sur le traitement. La Revue de Médecine Interne 20:5, pages 421-426.
Crossref
Crossref
Matthew H. Kulke & Robert J. Mayer. (1999) Carcinoid Tumors. New England Journal of Medicine 340:11, pages 858-868.
Crossref
Crossref
B. Eriksson & K. Öberg. (1999) Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook. Annals of Oncology 10, pages S31-S38.
Crossref
Crossref
Paola Tomassetti, Marina Migliori & Lucio Gullo. (1998) Slow-Release Lanreotide Treatment in Endocrine Gastrointestinal Tumors. American Journal of Gastroenterology 93:9, pages 1468-1471.
Crossref
Crossref
Jacob Lokich. (1998) Carcinoid Tumor Regression With High-Dose Octreotide Acetate. American Journal of Clinical Oncology 21:3, pages 246-247.
Crossref
Crossref
Allen S. Anderson, Daniel Krauss & Roberto Lang. (1997) Cardiovascular complications of malignant carcinoid disease. American Heart Journal 134:4, pages 693-702.
Crossref
Crossref
Paul C. Neary, Paul H. Redmond, Timothy Houghton, Gordon R. K. Watson & David Bouchier-Hayes. (1997) Carcinoid disease. Diseases of the Colon & Rectum 40:3, pages 349-362.
Crossref
Crossref
P Ruszniewski, M Ducreux, J A Chayvialle, J Blumberg, D Cloarec, H Michel, J M Raymond, J L Dupas, H Gouerou, R Jian, E Genestin, P Bernades & P Rougier. (1996) Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.. Gut 39:2, pages 279-283.
Crossref
Crossref
A. G. HARRIS & J. S. REDFERN. (2007) Octreotide treatment of carcinoid syndrome: analysis of published dose‐titration data. Alimentary Pharmacology & Therapeutics 9:4, pages 387-394.
Crossref
Crossref
Richard Cirelli & Stephen K. Tyring. (2012) Major Therapeutic Uses of Interferons. Clinical Immunotherapeutics 3:1, pages 27-87.
Crossref
Crossref
Christian Prinz, George Sachs, John H. Walsh, David H. Coy & S.Vincent Wu. (1994) The somatostatin receptor subtype on rat enterochromaffinlike cells. Gastroenterology 107:4, pages 1067-1074.
Crossref
Crossref
Leonard Saltz, Nancy Kemeny, Gary Schwartz & David Kelsen. (1994) A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 74:3, pages 958-961.
Crossref
Crossref